Our report (31) showed that the level of phosphorylated Akt was elevated in chemoresistant ovarian cancer cells and that treatment with an Akt inhibitor (LY294002) enhanced sensitivity to anticancer drugs. Here, AKT1 is linked to ovarian cancer.